Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669430 · ClinicalTrials.gov registry record · Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult, sponsored by GV20 Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 365
- Enrollment target
- 13
- Study locations
NCT05669430 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult that is actively recruiting participants, run by GV20 Therapeutics. The registered enrollment target is 365 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% lower). The trial reports 13 study locations across 12 states.
The verdict
NCT05669430, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by GV20 Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 365 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Conditions Studied
Interventions
- BIOLOGICAL GV20-0251
- BIOLOGICAL GV20-0251 and Pembrolizumab [KEYTRUDA®]
Study Locations (13)
Texas
- Oncology Consultants, P.A. - Houston
- The University of Texas M. D. Anderson Cancer Center - Houston
California
- The Angeles Clinic and Research Institute - Los Angeles
Colorado
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale University - New Haven
Florida
- Florida Cancer Specialists & Research Institute, LLC - Fort Myers
Indiana
- Community Health Network, Inc. - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-03-23 |
| Est. Completion | 2027-09-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669430
The ClinicalTrials.gov registry entry for NCT05669430 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (45% lower). The listed sponsor is GV20 Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which GV20-0251 is the first listed.
NCT05669430 reports 13 study locations spanning 12 distinct geographic areas - top geographies include Texas, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT05669430 about?
NCT05669430 is a clinical study titled "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies". This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
What is the current status of trial NCT05669430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 365 participants. The study started on 2023-03-23. Estimated completion is 2027-09-05.
What conditions does trial NCT05669430 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Adult, Cutaneous Melanoma, Refractory Cancer, Endometrial Carcinoma (EC).
What interventions are being tested in trial NCT05669430?
The interventions under investigation include: GV20-0251 (BIOLOGICAL), GV20-0251 and Pembrolizumab [KEYTRUDA®] (BIOLOGICAL).
Who is sponsoring clinical trial NCT05669430?
This trial is sponsored by GV20 Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669430 being conducted?
This trial has 13 study locations across California, Colorado, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.